1. India Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
J. B. Chemicals & Pharmaceuticals Limited

J. B. Chemicals & Pharmaceuticals Limited

JBCHEPHARM.BO
J. B. Chemicals & Pharmaceuticals LimitedIN flagBombay Stock Exchange
2,420.90
INR
+30.20
- -
389.55BMarket Cap
J. B. Chemicals & Pharmaceuticals Limited
JBCHEPHARM.BO
(Bombay Stock Exchange)

Recent

price

2,420.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
52.76
42.53
46.34
55.35
61.77
68.81
77.18
82.31
97.8
109.44
130.62
156.83
403.04
222.5
248.58
- -
263.98
Revenue per Share
8.25
40.06
4.69
3.63
5.92
9.57
10.71
8.24
11.77
17.1
28.98
24.93
53
35.66
42.45
- -
45.15
Basic EPS, GAAP
5.9
47.25
2.07
-4.39
3.27
-3.7
2.65
5.15
8.83
12.74
17.28
-34.72
-18.02
34.8
50.34
- -
- -
Free Cash Flow per Basic Share
1.16
24.35
0.59
1.76
1.75
11.06
0.34
0.62
1.27
8.86
4.74
8.25
16.5
10.13
15.26
- -
- -
Dividend per Share
13.94
25.43
27.82
29.29
26.43
32.87
48.55
56.32
68.04
77.82
103.53
120.21
276.83
163.68
189.92
- -
212.87
Book Value per Share
38.98
55.18
57.92
60.06
57.22
60.48
75.67
81.49
85.56
85.14
111.53
91.2
142.34
95.35
132.51
- -
182.83
Tangible Book Value per Share
169
169
169
169
170
170
170
168
164
159
155
155
77
155
155
- -
157
Basic Weighted Avg Shares
8,908
7,198
7,851
9,378
10,474
11,673
13,093
13,822
16,076
17,414
20,189
24,242
31,165
34,477
38,620
40,762
41,478
Sales/Revenue/Turnover
20.17
9.86
6.4
9.45
11.12
14.76
14.06
11.61
16.1
18.26
24.15
19.42
18.85
21.83
22.13
22.1
22.3
Operating Margin (%)
228
224
247
280
386
412
472
570
556
663
687
727
1,144
1,383
1,710
1,825
1,825
Depreciation Expense
1,393
6,779
794
615
1,004
1,625
1,841
1,383
1,935
2,720
4,480
3,854
4,098
5,526
6,596
7,095
7,095
Net Income, GAAP
15.68
19.63
23.3
29.67
31.02
23.36
19.81
28.48
32.41
21.93
24.86
23.54
26.16
26.46
25.67
25.5
25.5
Effective Tax Rate (%)
15.64
94.18
10.12
6.56
9.59
13.93
14.06
10.01
12.03
15.62
22.19
15.9
13.15
16.03
17.08
17.41
17.1
Profit Margin (%)
4,493
6,779
7,047
7,044
6,233
3,420
5,137
7,721
8,070
7,599
12,073
8,911
9,736
9,851
12,904
23,182
23,182
Working Capital
125
4
2
5
4
- -
- -
- -
- -
12
51
206
3,985
333
64
11
11
LT Debt
6,915
9,700
10,203
10,428
9,949
10,953
13,658
14,443
14,829
14,380
18,134
21,386
24,804
29,233
34,333
41,592
41,592
Total Equity
19.64
6.12
3.7
5.73
7.17
10.94
10.92
7.96
11.73
16.58
21.87
17.71
16.53
17.43
18.83
17.71
18.18
Return on Invested Capital (%)
27.29
158.58
16.57
11.63
17.81
25.64
23.07
15.14
18.44
22.61
30.95
21.79
18.82
20.78
22.66
22.56
22.56
Return on Capital (%)
34.68
203.68
17.62
12.71
21.26
32.28
26.31
15.64
18.74
23.09
31.56
22.29
20.5
23.63
24.04
22.54
22.54
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
192
- -
25
LT Borrowings
- -
- -
- -
LT Finance Leases
217
- -
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
157
- -
161
Market Capitalization
266,076
284,220
324,175

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
25,551
- -
29,094
Cash, Cash Equivalents & STI
9,014
- -
12,213
Accounts Receivable, Net
9,377
- -
7,809
Inventories
5,766
- -
6,834
Total Current Liabilities
6,742
- -
5,912
Payables & Accruals
- -
- -
- -
ST Debt
192
- -
25
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.66%
18.07%
21.14%
Free Cash Flow
-77.77%
-167.53%
-20.64%
Net Income, GAAP
18.77%
10.82%
7.56%
Sales/Revenue/Turnover
13.51%
15.37%
5.55%
Total Cash Common Dividend
92.01%
36.08%
32.17%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8,962
8,817
8,445
8,252
34,477
2025
10,044
10,006
9,635
9,495
38,620
2026
10,939
10,849
10,647
9,042
40,762

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9.2
9.72
8.62
- -
35.66
2025
11.39
11.24
10.46
9.36
42.45
2026
12.99
13.29
12.63
6.35
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
10.13
2025
- -
- -
- -
- -
15.26
2026
- -
- -
- -
- -
- -
Similar Companies
Livzon Pharmaceutical Group Inc. (1513.HK)
Molecule Holdings Inc. (EVRRF)
ShanXi C&Y Pharmaceutical Group Co., Ltd. (300254.SZ)
IDT Australia Limited (IDT.AX)
Planet 13 Holdings Inc. (PLNH)
Ascendis Health Limited (ASC.JO)
Business
J. B. Chemicals & Pharmaceuticals Limited J. B. Chemicals & Pharmaceuticals Limited engages in the development, manufacturing, and marketing of pharmaceutical formulations across more than 20 therapeutic categories including gastroenterology, anti-infectives, wound care, neonatology and pediatrics, gynecology, dental care, vitamins and minerals, hypertension, diabetes, nephrology, respiratory, pain management, dermatology, antivirals, and lozenges; its key brands encompass Metrogyl (metronidazole in tablets, suspensions, injections, gels, and ointments), Rantac (ranitidine and rabeprazole variants in tablets, injections, syrups, and capsules), Cilacar (cilnidipine in multiple strengths and fixed-dose combinations with telmisartan, metoprolol, or chlorthalidone), Nicardia (nifedipine retard and extended-release tablets), Cadomer (cadexomer iodine ointments), Panum (pantoprazole injections and capsules), Rabiet (rabeprazole combinations), Laxan and Laxolite (lactulose and polyethylene glycol solutions), and specialized offerings such as Favipill (favipiravir), Oltavir (oseltamivir), Nosmok (nicotine lozenges), and Ketodan (ketoanalogues for nephrology); dosage forms include tablets, capsules, injections, syrups, suspensions, ointments, gels, and lozenges with a focus on chronic therapies and niche segments like nicotine replacement therapy and contrast media. Founded in 1976 by J. B. Mody and headquartered in Mumbai, India, the company operates manufacturing facilities in Thane, Belapur, Ankleshwar, Panoli, and Daman, serving the Indian market through 600,000 pharmacies while exporting to over 40 regulated and semi-regulated international markets with wholly owned subsidiaries in South Africa and Russia. In June 2025, Torrent Pharmaceuticals Limited announced its acquisition of a 46.39% controlling stake from KKR via a share purchase agreement at INR 1,600 per share, to be followed by a merger under which JB Pharma shareholders will receive 51 Torrent shares for every 100 JB Pharma shares, strengthening Torrent's presence in the Indian pharmaceutical market.